Imatinib Cristers (Imatinib)

Imatinib blocks the activity of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases by binding to their ATP‑binding sites. This inhibition stops downstream signaling pathways that promote uncontrolled cell division, thereby reducing malignant cell proliferation in the diseases for which it is prescribed.

The specific dose of Imatinib Cristers is determined by the prescribing physician based on the patient’s diagnosis, disease stage, weight, renal and hepatic function, and other clinical factors. Healthcare professionals set the appropriate regimen and adjust it as needed during treatment.

Imatinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy unless the potential benefit justifies the risk. Breastfeeding is also discouraged because the drug is excreted in milk and may affect the infant.

To request Imatinib Cristers, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and is generally well‑tolerated. Newer agents such as dasatinib and nilotinib have higher potency and may be effective in imatinib‑resistant cases, but they can also have distinct side‑effect profiles. Choice of therapy depends on disease characteristics, prior treatment response and individual patient factors.

Imatinib tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Imatinib is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a full glass of water and follow the prescribing physician’s instructions regarding timing and any dietary considerations.

Serious adverse events include hepatotoxicity (liver injury), cardiotoxicity such as congestive heart failure, and severe neutropenia that can predispose to infections. Patients should be monitored regularly for liver function, cardiac status and blood counts throughout therapy.

Imatinib is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. It should also be avoided in pregnant women unless absolutely necessary, and used with caution in individuals with severe hepatic or renal impairment, uncontrolled cardiac disease, or those taking interacting medications listed as major contraindications.